Kaempferol inhibits the proliferation and migration of Epstein-Barr virus-positive diffuse large B-cell lymphoma cells

Suli Lu¹, Zhen Wang¹, Dae-jung Yang²*
¹Department of Medicine, Hunan Polytechnic of Environment and Biology, Hengyang City, Hunan Province 421005, China, 
²Department of Physical Therapy, Sehan University, Mokpo City, Jeollanam-do, 58447, Republic of Korea

*For correspondence: Email: pt6226@sehan.ac.kr; Tel: +82-010-6611-6264

Sent for review: 18 September 2023 Revised accepted: 2 February 2024

Abstract

Purpose: To assess the effect of kaempferol on the growth, apoptosis, and motility of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) cells, and to elucidate its mechanism of action.

Methods: Human DLBCL cells were used to generate EBV-positive (EBV +) cell line Pfeiffer. CCK-8, colony formation, flow cytometry (FCM), and immunoblot assays were employed to determine the effects of kaempferol on the growth and apoptosis of EBV + DLBCL cells. Cell motility was evaluated by Transwell and immunoblot assays. Immunoblot assay was further conducted to unravel the mechanism of action.

Results: Kaempferol inhibited the growth of EBV + DLBCL cells. It also enhanced the apoptosis of EBV + DLBCL cells, but inhibited the motility of the cells. Furthermore, kaempferol inhibited PI3K/AKT axis, thereby suppressing DLBCL.

Conclusion: Kaempferol inhibits the growth and motility of EBV + DLBCL cells via PI3K/AKT axis. It is therefore a potential drug for the treatment of DLBCL.

Keywords: Epstein-Barr virus (EBV), Diffuse large B-cell lymphoma (DLBCL), Kaempferol, Apoptosis, PI3K/AKT

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

INTRODUCTION

Epstein-Barr virus (EBV) was the first virus correlated with cancers. EBV causes a variety of cancers such as nasopharyngeal and stomach cancers [1], and is closely associated with the onset of diffuse large B-cell lymphoma (DLBCL) [2]. DLBCL is the most common type of non-Hodgkin’s lymphoma, accounting for 30 - 40 % of cases in different geographical regions [3]. Although the prognosis for DLBCL has improved overall, approximately one third of patients will experience relapse/refractory disease, and remains a leading cause of morbidity and death [4]. To enhance therapy, new therapeutic agents need to be developed to improve the cure rate of DLBCL. Kaempferol is a natural flavonoid with multiple pharmacological activities, including anticancer, anti-inflammatory, and anti-apoptotic effects [5]. Kaempferol has good antibacterial activity, and also has an effect on methicillin-
resistant Staphylococcus aureus (MRSA) [6]. Studies have shown that the anticancer effect of kaempferol in A375 cells is mediated by inducing apoptosis, cell cycle arrest, and inhibition of cell motility [7]. Kaempferol enhances the sensitivity of pancreatic cancer cells to erlotinib by restraining PI3K/AKT pathway as well as EGFR [8]. It increases the apoptosis of HeLa cells through PI3K/AKT and telomerase pathways. Kaempferol also reduces OX-LDL-induced apoptosis by blocking the up-regulation of autophagy in the PI3K/Akt /mTOR pathway in endothelial cells [9]. However, the mechanism of action of kaempferol in DLBCL remains unclear. There is evidence that PI3K/Akt is vital in EBV-induced malignancies. The major EBV oncoprotein latent membrane protein (LMP) 1 and LMP2A activate PI3K/Akt axis, thereby affecting cell survival, apoptosis, and genomic instability [5]. Its downstream target protein is also known to cause cancer, and its role in DLBCL has also been demonstrated. This study aims to examine the effect of kaempferol on DLBCL, and its potential clinical significance in the management of the disease.

EXPERIMENTAL

Cell culture and drug treatment

The DLBCL cell line Pfeiffer as well as B95-8 were purchased from ATCC and maintained in DMEM (Gbico, USA) supplemented with 10 % of FBS and incubated at 37 °C in a 5 % CO₂ incubator.

Construction of EBV + DLBCL model

One milliliter of the culture supernatant of B95-8 was centrifuged at 14,000 rpm at 4 °C for 90 min. An aliquot of 900 μL supernatant is removed, and the remaining 100 μL in the bottom was diluted to a final volume of 5 ml and used to maintain Pfeiffer cells for 72 h. Kaempferol (Sigma) was added to Pfeiffer cells at a concentration of 5/10/20 μM and kept for 24 h.

CCK-8 assay

The Pfeiffer cells were placed into 96-well plates, maintained for 48 h, incubated with CCK-8 (Beyotime, China) for 4 h, and the absorbance measured spectrophotometrically by multifunctional enzyme marker (VarioskanLUX, Thermo, USA) at a wavelength of 450 nm.

Colony formation assay

Pfeiffer cells (1000/well) were placed in 6-well plates as well as maintained in media (10 % FBS) for 14 days at 37 °C. The cells were fixed with PFA for 20 min and stained with 0.1 % crystal violet for 20 min, and then photographed by a fluorescence microscope (Axio A1, Zeiss, Germany).

Cell apoptosis assay

The Pfeiffer cells were fixed using 70 % ethanol. To determine cell apoptosis, the cells were stained with PI and FITC Annexin V at 4 °C and the levels of apoptosis were measured using FACSCalibur flow cytometer (BD Biosciences, Inc).

Transwell assay

The Pfeiffer cells were plated into the upper chambers with 20 % matrigel (invasion test) or without any matrigel (migration test) in DMEM (Gbico, USA) without any serum. After 24 h, the remaining cells were fixed and stained with the 0.1 % crystal violet for 15 min, and then photographed by a fluorescence microscope (Axio A1, Zeiss, Germany). The cell numbers were counted.

Immunoblot assay

Samples were separated by SDS-PAGE, and then transferred to a PVDF membrane. The proteins were blocked with 5 % milk for 1 h, and primary antibodies including Bax (Abcam, ab32503; 1:1000), Bcl-2 (Abcam, ab182858; 1:1000), cleaved caspase-3 (Abcam, ab32042; 1:1000), Akt (Abcam, ab8805; 1:1000), p-Akt (T308, Abcam, ab38449; 1:500), PI3K (Abcam, ab302958; 1:1000), GAPDH (Abcam, ab8245; 1:3000) were added as well as incubated at 4 °C overnight. The secondary antibodies were incubated for 1 h and photographed after chemiluminescence.

Statistical analysis

GraphPad 5.0 software was used for data analysis. The data are presented as mean ± SD. The data among groups were analyzed by student’s t test. P < 0.05 was considered statistically significant.

RESULTS

Kaempferol inhibits the growth of EBV + DLBCL cells

The chemical structure of Kaempferol is shown in Figure 1 A. The results showed that EBV treatment stimulated the growth of EBV + Pfeiffer cells (Figure 1 B). Treatment with kaempferol
suppressed the growth of EBV + Pfeiffer cells ($p < 0.05$, Figure 1 B). EBV treatment increased the colony numbers of Pfeiffer cells, whereas kaempferol treatment suppressed the proliferation of the cells after EBV treatment ($p < 0.05$; Figure 1 C). Thus, kaempferol inhibited the growth of EBV + DLBCL cells.

Kaempferol enhanced apoptosis of EBV + DLBCL cells

The results revealed that EBV treatment suppressed the apoptosis of Pfeiffer cells (Figure 2 A). However, treatment with kaempferol stimulated Pfeiffer cell apoptosis after EBV treatment ($p < 0.05$; Figure 2 A). Similarly, immunoblot assay data showed that EBV treatment increased Bcl-2 expression, but decreased Bax and cleaved caspase-3 expressions ($p < 0.05$, Figure 2 B). On the hand, treatment with kaempferol lowered the expression of Bcl-2, but increased the expression of Bax and cleaved caspase-3 in Pfeiffer cells after EBV treatment ($p < 0.05$; Figure 2 B). Thus, kaempferol increased the apoptosis of EBV + DLBCL cells.

Kaempferol inhibited the migration and invasion of EBV + DLBCL cells

Cell motility is vital in the progression of DLBCL. Transwell assay results showed that EBV treatment stimulated motility of Pfeiffer cells ($p < 0.05$; Figure 3 A and B). However, kaempferol treatment decreased both the migration and invasion of Pfeiffer cells after EBV treatment, suggesting the suppression of motility in EBV + DLBCL cells ($p < 0.05$; Figure 3 A and B). Thus, kaempferol inhibits the migration and invasion of EBV + DLBCL cells.
Kaempferol inhibits PI3K/AKT axis in EBV + DLBCL cells

EBV treatment increased the phosphorylation of PI3K and AKT in Pfeiffer cells (p < 0.05; Figure 4). However, Kaempferol treatment suppressed PI3K levels and AKT phosphorylation in Pfeiffer cells after EBV treatment (p < 0.05; Figure 4), indicating the regulatory effect of kaempferol on PI3K/AKT pathway in EBV+ DLBCL cells. Therefore, kaempferol inhibited PI3K/AKT axis in EBV + DLBCL cells.

Prospective studies have shown that the consumption of kaempferol significantly reduces the risk of ovarian cancer; 24 h of treatment with kaempferol suppressed the proliferation of cells [14]. In the present study, its anti-growth effects on DLBCL cells was found. Kaempferol also has anti-inflammatory effects, as it inhibits the expression of IL-4 and cyclooxygenase 2 by inhibiting Src kinase, and down-regulates the NF-κB pathway [19]. It inhibits angiogenesis and induces apoptosis of ovarian cancer cells.

In the present study, kaempferol suppressed the growth of DLBCL cells by targeting PI3K/AKT axis. The functions of PI3K/AKT axis include promoting cell metabolism, growth, survival and participation in the occurrence of cancer, chemotherapy resistance, and the regulation of angiogenesis [16]. Approved PI3K/Akt inhibitors, copanlisib, capivasertib, and ipatasertib are particularly effective against follicular lymphoma, ovarian cancer, breast cancer, and prostate cancer. DLBCL is often associated with the continued activation of PI3K/AKT axis [17]. NVP-BEZ235 is an inhibitor of PI3K that induces the apoptosis of DLBCL cells by inhibiting the expression of MCL-1, and inducing dephosphorylation of 4EBP1 [18]. On the other hand, kaempferol inhibits DLBCL by inhibiting PI3K/AKT axis.

CONCLUSION

Kaempferol blocks the growth of EBV+ DLBCL cells, stimulates apoptosis, and restrains the motility of EBV+ DLBCL cells by targeting PI3K/AKT axis. Therefore, it has a potential to be developed as a therapeutic agent for the management of DLBCL.

DECLARATIONS

Acknowledgements

This work was supported by the Education Department Foundation of Hunan Province of...
China (Grant no. 20C0695) and The Hunan Provincal Natural Science Foundation of China (Grant no. 2021JJ40185).

**Funding**

None provided.

**Ethical approval**

None provided.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Conflict of Interest**

No conflict of interest associated with this work.

**Contribution of Authors**

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Suli Lu, Zhen Wang and Dae-jung Yang designed the study and carried them out, supervised the data collection, analyzed and interpreted the data, prepared the manuscript for publication and reviewed the draft of the manuscript. All authors read and approved the manuscript for publication.

**Open Access**

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

**REFERENCES**


